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Stroke is a complex disease and one of the main causes of morbidity and mortality among the 
adult population. A huge variety of factors is known to influence patient outcome, including 
demographic variables, comorbidities or genetics. In this review, we expound what is known about 
the influence of clinical variables and related genetic risk factors on ischemic stroke outcome, 
focusing on acute and subacute outcome (within 24 to 48 hours after stroke and until day 10, 
respectively), as they are the first indicators of stroke damage. We searched the PubMed data base 
for articles that investigated the interaction between clinical variables or genetic factors and acute 
or subacute stroke outcome. A total of 61 studies were finally included in this review. Regarding 
the data collected, the variables consistently associated with acute stroke outcome are: glucose 
levels, blood pressure, presence of atrial fibrillation, prior statin treatment, stroke severity, type of 
acute treatment performed, severe neurological complications, leukocyte levels, and genetic risk 
factors. Further research and international efforts are required in this field, which should include 
genome-wide association studies. 
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Introduction
Stroke is one of the main causes of morbidity and mortality 
worldwide. In addition, as stroke is a main cause of disability in 
adults, there is a huge interest in improving the recovery of pa-
tients post-stroke.
A wide variety of factors are known to influence the out-
come1,2 after stroke, most of which are clinical variables related 
with the disease (stroke severity, etiology, etc.), cardiovascular 
risk factors (hypertension, heart failure, etc.) and other demo-
graphic variables (age, sex, etc.). However, there are studies 
that present contradictory results, making the relationship be-
tween clinical variables and stroke outcome not so clear. 
In addition, ischemic stroke is a complex disease with a sub-
stantial genetic component, the heritability of which ranges 
from 16% to 40%.3 Several genome-wide association studies 
(GWAS) have found genes associated with stroke risk and have 
been confirmed in independent studies.4-6 However, with the 
exception of two recent GWAS,7,8 the studies performed to find 
genetic variables associated with stroke outcome are candidate 
gene studies that have not been consistently replicated.9
Fast fibrinolysis or thrombectomy treatments are related 
with better recovery.10,11 This suggests that outcome-related 
molecular mechanisms are taking place in the first 24 to 48 
hours, the period defined as the acute phase of stroke. Acute 
outcome is defined as the outcome during the acute phase, 
and it is the first indicator of the impact of stroke on patient 
health. Acute outcome commonly reports the neurological sta-
tus of the patient, usually measured by the National Institute 
of Health Stroke Scale (NIHSS). This scale is a systematic as-
sessment tool that provides a quantitative measure of neuro-
logical deficit, evaluating different neurological aspects (con-
sciousness, language, neglect, etc.), and can be used to predict 
long term outcome.12,13 Consequently, acute outcome is associ-
ated with long-term outcome. 
In this review, we detailed what is known about the influ-
ence of clinical variables and related genetic risk factors on the 
acute and subacute outcome of patients after an ischemic 
stroke (within 24 to 48 hours after stroke and until day 10, re-
spectively). The aim of this review is to summarize all the 
knowledge acquired in recent years that could be useful for 
clinical practice and to perform studies in the field. 
Methods
We used the National Center for Biotechnology Information 
(NCBI) website to search in the PubMed database. The key-
words used were: “ischemic stroke,” “neurological” or “neuro-
logic,” “associated” or “predictor,” and “outcome.” We included 
articles that searched for a relationship of acute and subacute 
outcome with other clinical variables or genetic factors, and 
which were written in English or Spanish. We excluded animal 
trials, childhood trials and articles with less than 100 patients 
analyzed. Using these criteria, we found 1,321 different articles 
by May 2019, plus six specific articles that were searched for 
specific clinical variables. A total of 61 were finally included, 
excluding process is detailed in a flow diagram performed fol-
lowing Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA)14 statements (Figure 1).
Variables associated with acute outcome
We classified the variables into three fields: (1) baseline vari-
ables, (2) early outcome variables, and (3) genetic factors, 
which summarized a total of 38, 20, and three articles, respec-
tively (briefly detailed in Table 1).
Baseline variables
We defined as baseline variables those clinical factors present 
at the time of stroke onset and which are non-modifiable. 
These variables include demographics, comorbidities and phar-
macological treatments prior to stroke.
Figure 1. Flow diagram of the systematic review. 
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1,321 Records identied 
throught PubMed 
database searching
382 Records excluded by lters:
- Not in English or Spanish
- No-human studies
1,327 Records after duplicates removed
1,327 Records screened
452 Articles excluded:
- Childhood or infant studies
- Reviews and case-reports
- Studies with <100 participants
- No ischemic stroke studies
945 Abstracts assesed 
for eligibility
432 Full-text articles excluded:
- No acute outcome studied
- No relevant variable studied
493 Full-text articles 
assesed for eligibility
61 Studies included
6 Additional records 
identied throught 
specic searching
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Table 1. Detailed summary of each article included in this review
Study Outcome studied (definition) Cohort size (n) Variable studied Influence
Adams et al. 
(1999)12
7-day and 3-mo outcome (measured by Barthel Index and 
the Glasgow Outcome Scale)
1,281 Stroke severity Association
Kugler et al. 
(2003)16
Early recovery at 24 hr and 1 wk (Barthel Index) 2,219 Age Week influence (only at 1 wk)
Siegler et al. 
(2013)18
END (increase in NIHSS score of ≥2 points within 24 hr) 366 Age Independent association
Sex No association
Stroke severity Independent association
Yeo et al. 
(2013)19
ENI (reduction of ≥10 points on NIHSS score, or score of 4 or 
less, at 2 hr); CNI (reduction in NIHSS score of ≥8 points 
between 2 and 24 hr, or an NIHSS score of ≤4 at 24 hr)
263 Age Non-independent association
Sex Female gender associated with CNI
Stroke severity Independent predictor of CNI
Naess et al. 
(2014)20
7-day NIHSS, neurological worsening, mortality 1,867 Age >80 yr associated with worse outcome
Boehm et al. 
(2014)21
END (increase of ≥2 points on NIHSS score during first 24 hr 
after hospitalization)
4,925 Age Covariate
Sex Non-independent association
Ethnicity Non-independent association
Geng et al. 
(2017)22
END (increase of ≥2 points on NIHSS score during 1st wk 
after stroke)
1,064 Age No association
Sex No association
Diabetes mellitus Association with END
Hyperlipidemia LDL and total cholesterol were associ-
ated with END, but not triglycerides
Body mass index No association with END
Hassaballa et 
al. (2001)25
7-day and 3-mo outcome (measured by Glasgow Outcome 
Scale)
1,093 Ethnicity No association
Machumpu-
rath et al. 
(2011)26
ENR (improvement at least 50% on NIHSS score within 24 
hr)
161 Diabetes mellitus Association (hyperglycemia patients 
were less likely to have ENR)
Roquer et al. 
(2014)27
END (increase of ≥4 points on NIHSS score during first 72 hr 
after stroke)
Diabetes mellitus Association with END
Tang et al. 
(2016)28
Favorable neurological outcome (decrease of ≥4 points on 
NIHSS score or score of 0 at 24 hr, decrease of ≥8 points 
on NIHSS score or an score of 0 at 7 days; good functional 
outcome (mRS 0–1) at 3 mo
419 Diabetes mellitus Predictor of unfavorable outcome
Yi et al. 
(2016)29
END (increase of ≥2 points on NIHSS score within 10 days 
after admission)
426 Diabetes mellitus Association with END
Hui et al. 
(2018)30
END (increase of ≥2 points on NIHSS score within 5 days af-
ter stroke)
336 Diabetes mellitus Association with END
Forlivesi et al. 
(2018)31
No neurological improvement (NIHSS score at 24 hr ≥NIHSS 
score at baseline)
200 Diabetes mellitus Association with END
Vlcek et al. 
(2003)32
5-day outcome (Rankin Scale score >2 was defined as poor 
outcome)
372 Blood pressure Independent association with poor 
outcome (high diastolic BP)
Castillo et al. 
(2004)33
END (diminution on Canadian Stroke Scale of ≥1 points 
within first 48 hr); neurological outcome and mortality at 
3 mo
304 Blood pressure Extreme values of BP were associated 
with poor outcome
Pezzini et al. 
(2011)34
END (increase of ≥4 points on NIHSS score at 48 hr); 90-day 
functional status (measured by mRS)
264 Blood pressure Association, but dependent on stroke 
etiology
Geeganage et 
al. (2011)35
Death or neurological deterioration at 10 days 1,479 Blood pressure Association (high systolic BP)
Kvistad et al. 
(2013)36
CNR (no ischemic stroke symptoms at 24 hr); favorable 
short-term outcome (7-day mRS score of 0–1)
749 Blood pressure No association
Chung et al. 
(2015)37
END within 72 hr (increase of NIHSS score of ≥2 points) 1,116 Blood pressure Independent association with END 
(high systolic BP)
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Study Outcome studied (definition) Cohort size (n) Variable studied Influence
Gill et al. 
(2016)38
Early neurological outcome (improvement of NIHSS score at 
24 hr)
327 Blood pressure Independent association with ENR (low 
diastolic BP)
Kellert et al. 
(2017)39
ENI (improvement of ≥20% on NIHSS score, or improvement 
of ≥8 points on NIHSS score); long-term functional out-
come (mRS at 90 days)
28,976 Blood pressure No association
Kang et al. 
(2017)40
END (worsening by 2 points on NIHSS score) at 1, 2 and 3 
days
2,545 Blood pressure Independent association (systolic BP)
Keezer et al. 
(2008)41
Poor outcome at 10 days (Rankin Scale score >3) 364 Blood pressure Independent association with poor 
outcome (high and low BP values)
Sare et al. 
(2009)42
Neurological impairment (high 7-day NIHSS score than  
median NIHSS score); 90-day functional outcome  
(measured by mRS)
1,722 Blood pressure Association with neurological impair-
ment and poor outcome (high systol-
ic BP)
Zhang et al. 
(2018)43
END (increase in NIHSS score ≥4 or increase in Ia of NIHSS 
≥1 within 72 hr after recanalization treatment)
278 Blood pressure Independent association (high systolic 
BP)
Stroke etiology Independent association in intrave-
nous treated patients (large artery 
occlusion)
Sanák et al. 
(2010)45
24 hr and 7-day NIHSS score; 7-day mortality 157 Atrial fibrillation Association with 7-day mortality
Yaghi et al. 
(2016)46
ENR (decrease of ≥8 points in NIHSS score, or score of 0–1 
at 24 hr)
306 Atrial fibrillation Significantly more present on non-ENR 
group; independent negative associa-
tion with ENR
Restrepo et al. 
(2009)47
7-day NIHSS score 142 Hyperlipidemia Association with hyperlipidemia history
Choi et al. 
(2012)48
END (increase in NIHSS score of ≥4 at 24 hr) or ENR (reduc-
tion of NIHSS score of ≥4) within a week after stroke  
onset
736 Hyperlipidemia Extreme triglyceride levels associated 
with poor outcome
Branscheidt et 
al. (2016)51
ENR (improve >40% on NIHSS score at 24 hr); good  
outcome (mRS 0–1), favorable outcome (mRS 0–2) and  
mortality at 3 mo
896 Body mass index No association
Power et al. 
(2013)53
NIHSS score at baseline and 24 hr 229 Renal dysfunction Association
Lo et al. 
(2015)54
NIHSS improvement at 24 hr post-thrombolysis; 3-mo  
functional independence; 30-day mortality
199 Renal dysfunction No association
Yu et al. 
(2009)56
10-day functional outcome (mRS) 339 Prior statin treatment Association
Prior antithrombotic 
treatment
No association
Ní Chróinín et 
al. (2011)58
7- and 28-day functional outcome (mRS); 7-, 28-, 90-day, 
and 1-yr mortality
448 Prior statin treatment Associated with good outcome
Tsivgoulis et al. 
(2015)59
ECR (reduction of ≥10 points NIHSS score at 24 hr); good 
functional outcome (mRS 0–1) and mortality at 3 mo
1,660 Prior statin treatment Association with ECR
Yi et al. 
(2017)60
Neurological deterioration (increase of 2 points of NIHSS 
during 10 days after admission)
1,124 Prior statin treatment Concomitant use of antiplatelet and 
statins was associated with a favor-
able outcome
Prior antithrombotic 
treatment
Concomitant use of antiplatelet and 
statins was associated with a favor-
able outcome
Cappellari et 
al. (2011)61
Neurological improvement (reduction of ≥4 points in NIHSS 
score between 24 and 72 hr)
250 Prior statin treatment Prior and continued use of statins after 
stroke was associated with worse 
outcome
McAlpine et al. 
(2014)63
ENR (diminution on NIHSS score during first 24 hr after 
stroke)
158 Leukoaraiosis No association
Table 1. Continued
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Study Outcome studied (definition) Cohort size (n) Variable studied Influence
Saposnik et al. 
(2008)64
7-, 30-day, and 1-yr mortality; neurological deterioration 
(measured by Canadian Neurological Scale, worsening 
neurological deficit or deterioration in the level of  
consciousness)
3,631 Stroke severity Independent association
Kim et al. 
(2017)65
Early dramatic recovery (reduction of ≥8 points in NIHSS 
score or NIHSS score of 0–1 at 24 hr)
102 Stroke severity Independent association
Schmitz et al. 
(2017)66
ENR (NIHSS score improvement of ≥4 points at 24 hr) 557 Stroke etiology Cardioembolic stroke patients more 
likely to have ENR
Forlivesi et al. 
(2017)67
Neurological improvement (NIHSS score improvement of ≥4 
points or NIHSS score of 0) at 7 days
122 Stroke etiology Large artery strokes had lower odds ra-
tio than cardioembolic strokes
Ciccone et al. 
(2013)68
Neurologic deficit (NIHSS score ≥6) at 7 days; functional 
outcome (mRS) and mortality at 90 days
362 Acute treatment No association
Saver et al. 
(2015)69
NIHSS score changes at 27 hr; 3-mo functional outcome 
(mRS)
196 Acute treatment Mechanical thrombectomy after IVT 
treatment had higher NIHSS score 
decrease
Jovin et al. 
(2015)70
ENR (decrease of 4 points in NIHSS at 24 hr); functional 
(Barthel Index) and neurological (NIHSS score) outcome at 
90 days
206 Acute treatment Mechanical thrombectomy had better 
outcome
Fiorelli et al. 
(1999)71
END (increase of NIHSS score of ≥4 at 24 hr post-stroke  
onset); 3-mo disability (mRS score ≥1) and 3-mo death
609 Hemorrhagic  
transformation
Independent association (server HT)
Kablau et al. 
(2011)72
ENR (decrease of >4 on NIHSS score) and END (increase of 
>4 on NIHSS score) at 5 days
122 Hemorrhagic  
transformation
No association with END; non-severe 
HT more common on ENR
Dharmasaroja 
et al. (2011)73
ENR (NIHSS of 0 to 4 at 24 hr) 203 Hemorrhagic  
transformation
Inversely association with ENR
Gill et al. 
(2016)74
Reduction in NIHSS score after 24 hr 339 Hemorrhagic  
transformation
Inversely associated (server HT)
Boehme et al. 
(2013)77
END (NIHSS score increase of ≥2 at 24 hr) 334 Infections Non-independent association
Nardi et al. 
(2012)80
NIHSS score at baseline and at 72 hr; functional outcome 
(mRS) at discharge
811 Leukocyte counts Independent association
Kumar et al. 
(2013)81
Neurological deterioration (NIHSS score increase of ≥2 
within 24 hr)
292 Leukocyte counts Association
Tian et al. 
(2018)82
ENI (decrease NIHSS score of ≥4 points or complete recovery 
after 24 hr of intravenous treatment)
240 Leukocyte counts Independent association
Furlan et al. 
(2016)84
7-, 30-, and 90-day mortality rate 9,230 Blood platelet counts Non-independent association for 7-day 
mortality rate; associated with 30- 
and 90-day mortality
Turcato et al. 
(2017)85
Lack of neurological improvement at 7 days (no NIHSS score 
of 0, nor NIHSS score ≤4 from baseline)
316 Red blood cell counts Association with worse outcome
Pinho et al. 
(2018)86
NIHSS score at baseline and NIHSS score changes at 24 hr 602 Red blood cell counts No association
Furlan et al. 
(2016)87
7-, 30-, and 90-day mortality rate 9,230 Red blood cell counts High hemoglobin associated with high 
7-day mortality
Yi et al. 
(2017)88
10-day END (NIHSS score increase of ≥2 points) 396 Genetic factors CYP polymorphism associated with 
CYP plasma metabolites levels in END 
patients
Yi et al. 
(2017)89
10-day END (NIHSS score increase of ≥2 points) 297 Genetic factors 3 SNPs independent risk predictors for 
END
Yi et al. 
(2017)90
10-day END (NIHSS score increase of ≥2 points) 850 Genetic factors High-risk interactive genotypes were 
associated with END
END, early neurological deterioration; NIHSS, National Institute of Health Stroke Scale; ENI, early neurological improvement; CNI, continuous neurological im-
provement; LDL, low density lipoprotein; ENR, early neurological recovery; mRS, modified Rankin Scale; BP, blood pressure; CNR, complete neurological recov-
ery; ECR, early clinical recovery; HT, hemorrhagic transformation; CYP, cytochrome P450. 
Table 1. Continued
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Demographics
In the literature, age, sex and race are the demographic vari-
ables that have been most often related to the acute outcome 
of stroke. We found seven articles that reported association of 
age, sex and/or race to acute outcome.
The relation of stroke outcome with age is well established.15 
Some prior studies reported advancing age as a major negative 
factor in morbidity, mortality, and long-term stroke outcome. 
Regarding acute outcome, there are also several studies report-
ing its association with age.16-21 Kugler et al.16 analyzed a co-
hort of 2,219 patients to study the association between age 
and early recovery after ischemic stroke. The authors studied 
the functional status with the Barthel Index score at 24 hours 
after admission, at 1 week and at discharge. Linear multiple re-
gression showed significant independent negative influence of 
age on functional status at 1 week and at discharge, although 
this influence was weak. Other authors20 analyzed age as a di-
chotomic variable, dividing the cohort used into ≥80 or <80 
years old (592 and 1,275 patients were included in each group, 
respectively). They found that elder patients presented higher 
NIHSS score (at baseline and 7-day) and, at day 7, more neuro-
logical worsening and mortality. However, linear regression 
analysis showed that a higher 7-day NIHSS score was associ-
ated with a higher NIHSS score on admission and neurological 
worsening, but not with age ≥80. In contrast, in one study22 
with 1,064 patients that searched for variables associated with 
early neurological deterioration (END; defined as an increase of 
≥2 in NIHSS score during the first week after stroke), the au-
thors did not find significant differences in age between END 
and non-END patients. So, it seems that only older ages might 
be associated with worse acute and subacute outcome, al-
though the association of age with long-term outcome is 
much clearer.
Another demographic factor that influences stroke outcome is 
sex. Stroke is a dimorphic disease, and incidence and outcome 
differences between genders have been reported previously.23,24 
However, due to the difference in lifespan between men and 
women, age is an important factor to take into consideration 
when sex influence is analyzed in stroke outcome.18,19,21,22 
Boehme et al.21 performed a study to analyze the influence of 
sex and ethnicity on outcomes in which they included a total of 
4,925 patients, (27.6% women, 26.9% Afro-Americans). The 
outcomes of interest were admission NIHSS, END (defined as in-
crease of ≥2 points in NIHSS score within the first 24 hours after 
hospitalization) and functional outcome. Authors found differ-
ences in admission NIHSS and functional outcome depending on 
sex, although after adjusting by age and glucose on admission, 
the association was no longer significant. In addition, in a study22 
with 1,064 patients, sex was not associated with END at 1 week. 
So, it seems that the influence of sex on acute outcome might 
be dependent on other variables.
Although the role of ethnicity in stroke outcome is not wide-
ly considered, there are several studies reporting its influence 
on long-term outcome. However, in reference to acute out-
come, we found two studies21,25 that fulfilled our inclusion cri-
teria for this review (others did not reach sample size). In both 
studies, authors found no significant differences in acute out-
come between Afro-American patients and Caucasian patients.
Comorbidities
Among the long list of comorbidities that can influence out-
come, we included those that have been reported to be associ-
ated with stroke outcome: diabetes mellitus (DM), high blood 
pressure (BP), atrial fibrillation (AF), hyperlipidemia, body mass 
index (BMI), renal dysfunction, heart failure, prior dementia, 
and prior disability.
The presence of DM as well as elevated levels of glucose has 
been associated with worse long-term outcome and acute out-
come.22,26-31 The largest study27 that reported an association of 
DM with acute outcome included 1,088 patients. In this study, 
DM was associated with END (defined as an increase of ≥4 on 
NIHSS score during the first 72 hours after stroke). These studies 
indicate that DM or high levels of glucose on admission are as-
sociated with worse outcome in the acute and subacute phase.
We found several studies associating BP with acute neuro-
logical outcome.32-43 In one study with 1,116 patients included 
(210 with END), the authors37 analyzed the relationship among 
different measures of BP and END presented within 72 hours 
after stroke onset. Authors analyzed mean, maximum and min-
imum systolic and diastolic BP as well as the difference be-
tween maximum and minimum, the standard derivation and 
the coefficient of variation. The statistical analyses showed 
that all parameters, except diastolic BP mean, were indepen-
dently associated with END. Moreover, other authors38 also 
found a relationship between systolic BP and early neurological 
outcome (END) in a cohort of 327 ischemic stroke patients. 
Specifically, authors found that a reduction in systolic BP 24 
hours after thrombolysis was independently associated with 
improvement in NIHSS score at 24 hours after thrombolysis. All 
those findings suggest that BP (both diastolic and systolic) is 
influencing outcome, with high systolic BP and diminution of 
diastolic BP being associated with worse outcome. 
AF is one of the major risk factors for stroke44 and its impact 
on outcome has been widely studied, although mostly with 
reference to long-term outcome. Regarding acute outcome, 
one study45 analyzed a cohort of 157 patients treated with in-
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travenous thrombolysis (IVT). No association of AF with NIHSS 
was found at 24 hours or 7 days, and, even AF was significantly 
associated with 3-month modified Rankin Scale (mRS) and 
7-day mortality, this association was no longer significant in 
the multivariable regression analysis. On the other hand, in a 
more recent study,46 authors searched for factors associated 
with early neurological recovery (ENR; defined as a decrease of 
≥8 points in NIHSS score or a score of 0 to 1 at 24 hours) in a 
cohort of 306 patients treated with IVT. In this case, AF was 
significantly more present in the non-ENR group; this was also 
associated with 90-day mortality and 90-day disability. 
There is no clear association of hyperlipidemia comorbidity 
with stroke outcome, neither with acute outcome.22,47,48 In one 
study,47 the authors briefly reported an association between 
history of hyperlipidemia and 7-day NIHSS score in their co-
hort of 142 patients. Alternatively, other authors48 analyzed the 
relationship between triglycerides (TG) and END (increase in 
NIHSS score of ≥4 at 24 hours, or ENR, reduction of NIHSS 
score of ≥4) within a week after stroke onset. Authors include 
a total of 736 patients in their study. Statistical analysis 
showed that TG levels had a non-linear J-shape association 
with END and inverse J-shape association with ENR. Those re-
sults suggested that hypoTG and hyperTG were a risk factor for 
poor early outcome after ischemic stroke. In contrast, other 
study22 found that total cholesterol and low density lipoprotein 
levels were associated with END (defined as an increase of ≥2 
on NIHSS score in the first week after stroke) in a cohort of 
1,064 patients, but not TG. Consequently, it seems that lipid 
content may have an influence on acute outcome, but further 
research is needed to establish a definitive conclusion.
The BMI is associated with cardiovascular diseases, being 
overweight and obesity well established risk factors.49 Never-
theless, its influence on stroke outcome has been controversial 
due to the “obesity paradox.”50 A recent study51 included 896 
patients treated with IVT to determine the association of BMI 
with 3-month stroke outcome and, as secondary outcome, ENR 
at 24 hours (defined as an improvement of >40% on NIHSS 
score). In all cases, BMI was not associated with any studied 
outcome, even after adjusting for potential confounding fac-
tors. Moreover, these findings were observed in another study22 
with 1,064 patients, where no association was found between 
BMI and 1-week END. In conclusion, it seems that BMI had no 
impact on acute outcome.
Renal dysfunction is a cardiovascular risk factor commonly 
found in stroke patients,52 it is defined as estimated glomerular 
filtration rate (eGFR) <60 mL/min. We found two studies that 
analyzed the role of eGFR with acute outcome.53,54 On one 
hand, one study53 analyzed the association of renal dysfunction 
in a cohort of 229 ischemic stroke patients treated with IVT. 
The authors found that patients with eGFR <60 mL/min had 
higher NIHSS scores at baseline and at 24 hours. On the other 
hand, another study,54 with 199 patients recruited, did not find 
any significant difference in NIHSS improvement at 24 hours 
post-thrombolysis, functional independence at 3 months, nor 
30-day mortality between patients with or without renal dys-
function. As a consequence, it is not clear if renal dysfunction 
could be associated with worse acute outcome. Further re-
search is needed to clarify these controversial results.
For heart failure, prior dementia or prior disability we did not 
find any study related with acute outcome. Nonetheless, other 
studies had reported the influence of these variables on long-
term outcome.1,55
Pharmacological treatments prior to stroke
Statins are prescribed for treatment of hypercholesterolemia. 
In stroke, statins are reported to reduce the risk of cerebrovas-
cular events, and their role in outcome improvement have been 
highly studied with controversial results (several studies47,56-60 
found that statins improved outcome, although another study61 
did not find this association). Besides, antithrombotic drugs are 
used to prevent stroke recurrence and several studies have also 
analyzed the influence of prior antithrombotic treatments on 
acute outcome.56,60 In the most recent study,60 the authors used 
a cohort of 1,124 patients to examine the association of statins 
and antiplatelet pretreatments with neurological deterioration 
after stroke (defined as an increase of 2 points on NIHSS dur-
ing 10 days after admission). They found that only concomitant 
use of antiplatelet and statins was associated with a favorable 
outcome. Moreover, another study56 with a cohort of 339 pa-
tients observed that statins pretreatment was associated with 
good outcome (mRS score of 0 to 3) at 10 days, as well as the 
concomitant use of antihypertensive, antiplatelet and statins 
drugs, but not with the use of antiplatelet drugs alone. Fur-
thermore, Tsivgoulis et al.59 found that use of statins prior to 
stroke was independently related with early clinical neurologi-
cal recovery in their cohort of 1,660 patients, although it was 
not related with good 3-month outcome.
In summary, prior use of only antiplatelet drugs is not 
enough to influence acute stroke outcome. In contrast, treat-
ment with statins prior to stroke could be associated with bet-
ter acute outcome, but not with long-term outcome.
Early outcome variables
Early outcome variables are those that can be described during 
the first few hours after stroke symptoms onset, such as: leu-
koaraiosis, stroke severity, acute treatment performed, neuro-
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logical/clinical complications, levels of blood constituents, and, 
in some cases, stroke etiology.
Leukoaraiosis
Leukoaraiosis is a radiological phenomenon which represents 
white matter lesions and is commonly observed in elderly people. 
Patients with leukoaraiosis are described as more likely to suffer 
ischemic stroke and it has been demonstrated that leukoaraiosis 
is more common and more severe in ischemic stroke patients 
than in healthy people.62 However, little is known about the role 
of leukoaraiosis on acute stroke outcome, and most of the stud-
ies have been performed with small cohorts. In the largest 
study63 that we found, the authors analyzed the association of 
leukoaraiosis with ENR (defined as diminution on NIHSS score 
during the first 24 hours after stroke) in 158 patients and did not 
find any association. However, larger studies are warranted to 
clarify the role of leukoaraiosis in acute outcome.
Stroke severity
Stroke severity is one of the variables most strongly correlated 
with outcome, and its association with acute outcome has 
been widely reported.12,17-19,64,65 In the largest study,64 a cohort 
of 3,631 ischemic stroke patients was analyzed to describe the 
influence of clinical variables on 7-, 30-day, and 1-year mor-
tality. The authors found that stroke severity (measured by Ca-
nadian Neurological Scale) was independently associated with 
mortality at all three time points, as well as neurological dete-
rioration during hospitalization. Stroke severity therefore seems 
to be more highly related with acute outcome than other fac-
tors, as its association is always reported as an independent 
association after multivariable regression analysis. 
Stroke etiology
In one study,66 authors observed that cardioembolic (CE) stroke 
patients were more likely to have ENR (NIHSS score improve-
ment of ≥4 points at 24 hours) than large vessel disease (LVD) 
etiology in their cohort of 557 ischemic stroke patients; no dif-
ferences were found between LVD and the other Trial of Org 
10172 in Acute Stroke Treatment (TOAST) categories. Moreover, 
another study67 found similar results in their cohort of 122 
ischemic stroke patients when analyzing 7-day neurological 
improvement depending on stroke subtype. So, it seems that 
LVD is associated with worse acute outcome in terms of recov-
ery compared with CE stroke etiology. However, both studies 
were performed on patients undergoing thrombolysis, so fur-
ther research is needed to clarify the role of stroke etiology in 
acute stroke outcome.
Acute treatments
By acute treatments we refer to those treatments performed to 
treat ischemic stroke during the acute phase, commonly 
thrombolysis and/or thrombectomy. We found several studies 
about their influence on acute outcome.68-70 In one study,69 au-
thors tested the efficacy of mechanical thrombectomy after IVT 
compared to the use of IVT alone. A total of 196 patients un-
derwent randomization, with 98 patients in each group; there 
were no significant differences in demographic or clinical char-
acteristics between groups. The primary outcome of the study 
was functional outcome at 3 months, and secondary outcome 
was NIHSS changes at 27 hours. They found that combined 
treatment had a significantly better outcome at 3 months and 
a higher decrease in NIHSS score, with a better neurological 
status at 27 hours. Moreover, another study70 found similar re-
sults in a cohort of 206 patients divided into two groups: med-
ical therapy (control group; including IVT when eligible) and 
medical therapy combined with endovascular therapy by Soli-
taire stent retriever (thrombectomy group). They found that the 
thrombectomy group presented a higher rate of ENR (defined 
as a decrease of 4 points in NIHSS at 24 hours) as well as bet-
ter 90-day functional and neurological outcome (by Barthel 
Index score and NIHSS score respectively). In conclusion, me-
chanical thrombectomy (after IVT or not) is associated with a 
better acute and long-term outcome.
Neurological complications
By neurological complications we mean those medical compli-
cations that may conclude with cognition deficit and could oc-
cur during the first days of hospitalization. We focused on 
hemorrhagic transformation (HT) and edema, due to their 
prevalence during acute and subacute phase.
HT is defined as an intracranial bleeding commonly detected 
by imaging (computed tomography or magnetic resonance im-
aging). In the literature, HT is commonly linked with stroke 
outcome and frequently more detected in IVT treated patients. 
Nevertheless, influence of HT on stroke outcome depends on 
its severity.71-74 Fiorelli et al.71 analyzed the influence of HT on 
ischemic stroke outcome: END (increase of NIHSS score of ≥4 
at 24 hours post-stroke onset), 3-month disability (Rankin 
score ≥1) and 3-month death. Authors used a cohort of 609 
patients treated with IVT or placebo, and used the European 
Cooperative Acute Stroke Study I (ECASS I) protocol for HT 
classification (hemorrhagic infarct 1 or 2 [HI-1, H1-2]; paren-
chymal hematoma 1 or 2 [PH-1, PH-2]). They found that PH-2 
subtype entailed higher risk of END and 3-month death, inde-
pendently of age and extent of initial ischemic damage, in pla-
cebo and IVT patients. On the other hand, in the most recent 
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study74 authors used a cohort of 339 stroke patients to analyze 
the influence of HT on stroke outcome at 24 hours after 
thrombolysis measured by NIHSS. In this case, authors found 
that PH-2 subtype of HT was associated with worse neurologi-
cal outcome. The authors concluded that mild to moderate HT 
should not be considered a complication and might be related 
with successful treatment and vascular recanalization. In sum-
mary, we may conclude that severe HT (i.e., PH-1, PH-2) is as-
sociated with worse acute outcome.
Cerebral edema is an accumulation of fluid in brain tissue, 
commonly observed in the acute phase of stroke. This neuro-
logical complication seems to have a more direct effect on 
stroke long-term outcome than HT.75 However, we found no 
references in the literature to its influence on acute or sub-
acute outcome.
Other clinical complications
As clinical complications, we included infections, gastrointesti-
nal bleeding, and dysphagia. These three are the most com-
monly observed during the first days of hospitalization after 
stroke.76 However, in reference to acute or subacute outcome, 
we only found information about infections. In Boehme et al.,77 
the authors analyzed the influence of infections on acute out-
come of ischemic stroke patients for the first time, with END 
being the primary outcome (NIHSS score increase of ≥2 at 24 
hours). They used a cohort of 334 patients, of which 77 had an 
infection, and classified the infections as present on admission 
(POA; infection diagnosed within the first 24 hours) and hospi-
tal-acquired infections (HAIs; infection diagnosed after 24 
hours). Authors found that both POA and HAIs were associated 
with END, but after adjustment by age, NIHSS at baseline, glu-
cose on admission and IVT treatment, only HAIs remained sig-
nificant. Thus, as END was defined at 24 hours, and HAIs were 
posterior to 24 hours, we cannot conclude that infections af-
fect acute outcome. And, as POA were not independently asso-
ciated with END, it seems that the influence of prior infections 
on acute outcome is much lower than the influence of other 
variables, such as stroke severity or acute treatment.
Blood constituents
As there is an important inflammatory response during stroke 
events, the cells implicated in the immune system are likely to 
be associated with stroke outcome. In addition, it is reported 
that neutrophils are related with the blood brain barrier break-
down and their infiltration seems to be associated with higher 
inflammation and have a role in cerebral ischemia,78 and higher 
neutrophil counts before thrombolysis have been associated 
with worse 3-month outcomes.79 However, there are few stud-
ies analyzing the relation of leukocytes (including neutrophils 
and lymphocytes) with acute stroke outcome.80-82 In Nardi et 
al.,80 authors aimed to establish whether admission leukocyte 
count affects early stroke outcome. A total of 811 ischemic 
stroke patients were included in the study. NIHSS score was 
measured at baseline and after 72 hours, as well as mRS at dis-
charge, and leukocytes counts were measured within 12 hours 
post-stroke onset. Authors found that higher leukocytes counts 
were independently associated with high NIHSS scores at base-
line and 72 hours, and with poor functional outcome at dis-
charge. So, it seems that leukocyte counts have an impact on 
subacute outcome independently of age or NIHSS at baseline.
Blood platelet counts (BPC) were previously associated with 
ischemic stroke risk,83 although their influence on outcome is 
poorly described. The study by Furlan et al.84 described the as-
sociation of abnormal BPC with outcome. They analyzed the 
mortality rate in a cohort of 9,230 patients at 7, 30, and 90 
days post-stroke. In a univariate analysis, all variables were as-
sociated with BPC, but after adjustment by principal confound-
ers, only 30- and 90-day mortality remains significant. So, it 
seems that abnormal BPC (such as thrombocytopenia or 
thrombocytosis) is associated with long term outcome but not 
with acute outcome. However, further studies are needed to 
confirm these findings.
Red blood cell counts and hemoglobin levels could influence 
the reoxygenation during acute ischemic stroke and, in turn, 
the degree of neurological damage. Turcato et al.85 analyzed 
the influence of red blood cell distribution width (RDW) on 
stroke outcome in a cohort of 316 ischemic stroke patients. 
Authors analyzed the association of RDW with lack of neuro-
logical improvement at 7 days (no NIHSS score of 0, nor NIHSS 
score ≤4 from baseline). They found that patients with RDW 
≥14.5% showed a significantly lower decrease in NIHSS score 
at 24 hours and 7 days from baseline compared to patients 
with RDW <14.5%. A more recent study,86 which included 602 
patients, found that RDW was not associated with NIHSS nor 
NIHSS changes at 24 hours. Nevertheless, RDW was associated 
with 1-year survival and better 3-month functional outcome in 
older patients (≥75 years). On the other hand, Furlan et al.87 
analyzed the influence of blood hemoglobin concentration 
(HGB) on stroke severity and outcome after ischemic stroke in 
a large cohort of 9,230 ischemic stroke patients. They found 
that high HGB, but not low HGB, was an independent predictor 
of increased 7-day mortality compared to normal HGB. In sum-
mary, it seems that high oxygen availability in acute phase of 
stroke is associated with worse acute and subacute outcome, 
although more research is needed.
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Genetic factors
There are several reports searching for the relationship of po-
tential candidate genes with stroke outcome, most of them 
performed on animal models. However, regarding acute or sub-
acute outcome, we found very few articles that attempted to 
find genetic factors associated with outcome.88-90 The genes of 
interest in those studies were: cytochrome P450 (CYP), cyclo-
oxygenase-2 (COX-2), prostaglandin I2 synthase (PTGIS), 
thromboxane A synthase 1 (TBXAS1), purinergic receptor P2Y1 
(P2RY1), and integrin subunit beta 3 (ITGB3, or GPIIa). In those 
studies, authors found different single nucleotide polymor-
phisms (SNPs) independently associated with END at 10 days 
after stroke (defined as a NIHSS score increase of ≥2). However, 
no replication was performed in those studies. Only the SNP of 
COX-2, rs20417,was independently associated to END in two 
different studies.89,90 So, it seems that genetic factors could 
have an influence on END, although further in-depth research 
is needed in this area. Additionally, in reference to long-term 
stroke outcome, two GWAS (Genetic contribution to functional 
Outcome and Disability after Stroke [GODS]7 and Genetics of 
Ischemic Stroke functional outCOME [GISCOME]8 studies, with 
1,791 and 6,165 participants, respectively) have been recently 
published with remarkable results. One study7 had found a lo-
cus located within a candidate gene, confirmed by an external 
replication. These studies are beginning to clarify the influence 
of genetics on patient recovery, which can help us to under-
stand all the mechanisms involved.
Conclusions
Among all the clinical variables that were included in this re-
view, there are few variables strong and clearly associated with 
acute or subacute stroke outcome (Table 2). These are: glucose 
levels or DM, BP, presence of AF, prior statin treatment, stroke 
severity, type of acute treatment performed, sever neurological 
complications (PH-2), and leukocytes levels. These clinical vari-
ables can easily be collected, so might be useful for prognosis 
of acute outcome. Other clinical variables that might be asso-
ciated include hyperlipidemia, renal dysfunction, BPCs, and red 
blood cells (or hemoglobin) levels. For these variables, further 
research is required to establish a clear association.
It is surprising that age and sex, which are used as covariate 
in association studies such as GWAS, had a very weak influ-
ence on acute and subacute stroke outcome. However, it has 
been observed that those variables had an important influence 
on long-term outcome. Likewise, it is interesting that BMI is 
clearly not associated with acute stroke outcome, in contrast 
with the controversy observed about the relationship of BMI 
with long-term outcome. Additionally, it is important to high-
light the influence of initial stroke severity on acute outcome, 
to the extent that it has been reported as an independent pre-
dictor in different studies and commonly included as covariate 
for predictor scales.
Regarding genetic factors, there are several SNPs reported to 
be associated with neurological deterioration. However, further 
studies are needed to validate these data, as there is a lack of 
replication in most of the studies performed. Only rs20417 (lo-
cated in COX-2 gene) was reported to be associated with END 
in two different studies.89,90 Alternatively, genetic factors have 
been found to be associated with long-term outcome,7,8 pro-
viding evidence of the utility of GWAS for exploring the genes 
associated with stroke outcome. Genetic analyses in this field 
may be useful to understand the molecular mechanisms behind 
the acute stroke outcome, and are required as no GWAS are 
currently reported.
As limitation, we considered that there is a lack of studies 
with enough statistical power to detect associations and per-
form consistent replication analysis, and also a no-consensus 
definition of the acute variable studied (i.e., END) makes im-
possible to perform meta-analyses, an approach required in or-
der to obtain new qualitative and quantitative findings.
Table 2. Reviewed variables classified depending on its association with 
stroke outcome
Stroke outcome 
(acute and  
sub-acute)
Baseline variable
Early outcome  
variable
Genetic factor
Associated Glucose levels or 
diabetes melli-
tus
Blood pressure
Atrial fibrillation
Prior statin 
treatment
Stroke severity
Type of acute treat-
ment performed
Sever neurological 
complications 
(PH-2)
Leukocyte levels
rs20417 (located 
in COX-2 gene)
Might associat-
ed
Hyperlipidemia
Renal dysfunc-
tion
Leukoaraiosis
Stroke etiology
Prior infections
Blood platelet 
counts
Red blood cells or 
hemoglobin levels
Candidate genes: 
CYP
PTGIS
TBXAS1
P2RY1
ITGB3
Unknown Heart failure
Prior dementia
Prior disability
Cerebral edema
Gastrointestinal 
bleeding
Dysphagia
No associated Age
Sex
Ethnicity
Body mass index
PH-2, parenchymal hematoma 2; COX-2, cyclooxygenase-2; CYP, cyto-
chrome P450; PTGIS, prostaglandin I2 synthase; TBXAS1, thromboxane A 
synthase 1; P2RY1, purinergic receptor P2Y1; ITGB3, integrin subunit beta 3.
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In conclusion, our review provides a “state of the art” of this 
important field, reporting all the variables consistently associated 
with stroke early outcome and highlighting the lack of genetic 
studies. However, further research is required in this field. Analy-
sis of acute and subacute outcome is important to understand 
the molecular mechanisms behind acute and long-term recovery 
and, finally, treat or prevent the worsening after stroke.
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